Detecting seronegative-early HIV infections among adult versus student Kenyan blood donors, by using stimmunology

Experimental Biology and Medicine

Volumn 234, Issue 8, 2009, Pages 931-939

  Mumo, Jasper ^a   Vansover, Ami ^b   Jehuda Cohen, Tamar ^c  

^a UNIVERSITY OF NAIROBI   (Kenya)

^b TEL AVIV UNIVERSITY   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

AIDS; Blood donors; HIV; Incidence; Kenya; Prevalence; Seronegative; Stimmunology; Window period

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BLOOD DONOR; CONTROLLED STUDY; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; KENYA; LYMPHOCYTE TRANSFORMATION TEST; MAJOR CLINICAL STUDY; SEROCONVERSION; VIRUS CARRIER;

ADOLESCENT; ADULT; BLOOD DONORS; BLOTTING, WESTERN; DIAGNOSTIC TECHNIQUES AND PROCEDURES; EARLY DIAGNOSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HIV ANTIBODIES; HIV INFECTIONS; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMANS; KENYA; LYMPHOCYTE ACTIVATION; POLYMERASE CHAIN REACTION; PREGNANCY; STUDENTS;

EID: 68149175258     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.3181/0812-RM-372     Document Type: Article

References (29)

1. Jackson BR, Busch MP, Stramer SL, AuBuchon JP. The costeffectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 43:721-729, 2003.
2. Litvak E, Siegel JE, Pauker SG, Lallemant M, Fineberg HV, Weinstein MC. Whose blood is safer? The effect of the stage of the epidemic on screening for HIV. Med Decis Making 17:455-463, 1997.
3. Shearer GM, Clerici M. Protective immunity against HIV infection: Has nature done the experiment for us? Immunol Today 17:21-24, 1996.
4. Gendler SA, Pascuccio MS. Routine HIV screening among blood donors in Buenos Aires (Argentina): Results from six years' experience and report of a single window-period donation. Enferm Infecc Microbiol Clin 25:82-90, 2007.
5. Alamawi S, Abutaleb A, Qasem L, Masoud S, Memish Z, Al Khairy K, Kheir O, Bernvil S, Hajeer AH. HIV-1 p24 antigen testing in blood banks: Results from Saudi Arabia. Br J Biomed Sci 60:102-104, 2003.
6. Mundee Y, Kamtorn N, Chaiyaphruk S, Nantachit N, Ness PM, Nelson KE. Infectious disease markers in blood donors in northern Thailand. Transfusion 35:264-267, 1995.
7. Strathdee SA, O'Shaughnessy MV, Schechter MT. HIV in the blood supply: Nothing to fear but fear itself. CMAJ 157:391-392, 1997.
8. Velati C, Fomiatti L, Baruffi L, Romano L, Zanetti A. Impact of nucleic acid amplification technology (NAT) in Italy in the three years following implementation (2001-2003). Euro Surveill 10:12-14, 2005.
9. Pillonel J, Laperche S. Trends in risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2003 and impact of nucleic acid testing (NAT). Euro Surveill 10:5-8, 2005.
10. Alvarez do Barrio M, Gonzalez Diez R, Hernandez Sanchez JM, Oyonarte Gomez S. Residual risk of transfusion-transmitted viral infections in Spain, 1997-2002, and impact of nucleic acid testing. Euro Surveill 10:20-22, 2005.
11. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 334:1685-1690, 1996.
12. Busch MP, Glynn SA, Stramer SL, Strong DM, Caglioti S, Wright DJ, Pappalardo B, Kleinman SH. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 45:254-264, 2005.
13. Busch MP, Kleinman SH, Nemo GJ. Current and emerging infectious risks of blood transfusions. JAMA 289:959-962, 2003.
14. Lindback S, Thorstensson R, Karlsson AC, von Sydow M, Flamholc L, Blaxhult A, Sonnerborg A, Biberfeld G, Gaines H. Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure. Karolinska Institute Primary HIV Infection Study Group. AIDS 14:2333-2339, 2000.
15. Ciesielski CA, Metler RP. Duration of time between exposure and seroconversion in healthcare workers with occupationally acquired infection with human immunodeficiency virus. Am J Med 102:115-116, 1997.
16. Jehuda-Cohen T, Slade BA, Powell JD, Villinger F, De B, Folks TM, McClure HM, Sell KW, Ahmed-Ansari A. Polyclonal B-cell activation reveals antibodies against human immunodeficiency virus type 1 (HIV-1) in HIV-1-seronegative individuals. Proc Natl Acad Sci U S A 87:3972-3976, 1990.
17. Bar-Yehuda S, Weisman Z, Kalinkovich A, Vonsover A, Zlotnikov S, Jehuda-Cohen T, Bentwich Z. High prevalence of HIV-specific immunity in seronegative Ethiopian immigrants in Israel. AIDS 11:117-118, 1997.
18. Jehuda-Cohen T. A new look at HIV transmission from seropositive mothers to their infants: The facts beyond serology. Isr J Med Sci 30:364-368, 1994.
19. Jehuda-Cohen T, Mumo JM, Bwayo JJ, Pezzella M. Detection of HIV infection during window period using polyclonal B-cell activation test. AIDS 11:124-125, 1997.
20. Jehuda-Cohen T, Powell JD, Sell KW, Villinger F, Lockwood E, McClure HM, Ahmed-Ansari A. Transmission of retroviral infection by transfusion of seronegative blood in nonhuman primates. J Infect Dis 163:1223-1228, 1991.
21. Kenya and HIV/AIDS. In: USAID Population Health and Nutrition Programs HIV/AIDS Division and Implementing AIDS Prevention and Care (IMPACT) Project, 2006.
22. Chemtob D, Grossman Z. Epidemiology of adult and adolescent HIV infection in Israel: A country of immigration. Int J STD AIDS 15:691-696, 2004.
23. Lifson AR, Stanley M, Pane J, O'Malley PM, Wilber JC, Stanley A, Jeffery B, Rutherford GW, Sohmer PR. Detection of human immunodeficiency virus DNA using the polymerase chain reaction in a well-characterized group of homosexual and bisexual men. J Infect Dis 161:436-439, 1990.
24. Jehuda-Cohen T, Powell JD, Villinger F, Mayne AE, Sell KW, Ansari AA. Evidence for simian immunodeficiency virus-specific IgM and IgG response in peripheral blood mononuclear cells of serum enzymelinked immunosorbent assay-negative nonhuman primates. J Acquir Immune Defic Syndr 7:539-550, 1994.
25. Busch MP, Lee LL, Satten GA, Henrard DR, Farzadegan H, Nelson KE, Read S, Dodd RY, Petersen LR. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: Implications for screening of blood and tissue donors. Transfusion 35:91-97, 1995.
26. Yasui Y, Yanai H, Sawanpanyalert P, Tanaka H. A statistical method for the estimation of window-period risk of transfusion-transmitted HIV in donor screening under non-steady state. Biostatistics 3:133-143, 2002.
27. Kenya National Guidelines for Research and Development of HIV/AIDS Vaccines: Kenya Ministry of Health, 2005.
28. Jehuda-Cohen T, Novikov l. HIV-1 infection among Ethiopian immigrants to Israel - enhanced in-vitro antibody stimulation for estimating the length of the window-period. AIDS Hum Retroviruses 25:in press, 2009.
29. Fiebig EW, Heldebrant CM, Smith RI, Conrad AJ, Delwart EL, Busch MP. Intermittent low-level viremia in very early primary HIV-1 infection. J Acquir Immune Defic Syndr 39:133-137, 2005.